RareResearch.AI
← Back to atlas

K705N

Category 3/4 — Most DruggablePathogenicLumenal · predictedσ-1 candidateEditorial
LysineAsparagine at position 705 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Lysine → Asparagine at position 705 in wolframin's C-terminal lumenal domain. ClinVar Pathogenic. AlphaMissense 0.990 (near-maximum), DynaMut2 ΔΔG -0.66 kcal/mol (destabilising). A charge-loss variant in the high-confidence lumenal fold.

Interactive 3D Structure

Wild-type reference
Wild-type K705 — ionic bond to D801
Fullscreen ↗
DynaMut2 mutant · K705N
Mutant N705 — ionic bond to D801 lost (5 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

5 lost3 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Ionic bondD801Lost
Hydrogen bondT778T778Preserved
Hydrogen bondD801Lost
Hydrogen bondQ819Gained
Polar contactR703R703Preserved
Polar contactT778T778Preserved
Polar contactG780Gained
Polar contactD801Lost
Polar contactQ819Q819Preserved
Van der WaalsD801Lost
Van der WaalsQ819Gained
HydrophobicT778Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.66kcal/mol
Destabilising — mild
AlphaMissense
0.990
LPath
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditions(no specific conditions catalogued for K705N — ClinVar Pathogenic by review evidence)
InheritanceInheritance not specified. ClinVar Pathogenic classification establishes clinical relevance.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2115G>T
ClinVar accessionVCV003637013
Last evaluated2024/08/16 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Structural Context

Position 705 sits in wolframin's C-terminal lumenal domain. The AlphaFold model places K705 within 5 Å of TYR706 (2.4 Å), PHE704 (2.5 Å), THR778 (3.6 Å, a longer-range contact across the lumenal fold), GLN819 (4.4 Å, another distal contact), and ARG703 (4.5 Å). The neighbors are aromatic-rich (Y706, F704), polar (T778, Q819), and basic (R703, K705 itself).

The wild-type lysine at 705 carries a positive charge that likely participates in a salt-bridge or hydrogen-bonding network with the nearby threonine (T778) and glutamine (Q819) residues — both H-bond acceptors. The lysine side chain is long enough (4-carbon alkyl + amine) to reach across to these distal positions, contributing to a folded geometry that brings sequence-distant residues into proximity.

Replacing lysine with asparagine removes the positive charge and shortens the side chain. The polar amide of asparagine can still hydrogen-bond, but it can no longer reach the same distal positions as the lysine's longer chain. The local fold geometry that depends on the K705-T778 or K705-Q819 contact is perturbed.

DynaMut2's |ΔΔG| of 0.66 reflects the modest energetic cost of the fold rearrangement. AlphaMissense's 0.990 score captures the severity of the lost functional contact.

Amino-acid chemistry
Lysine (K) → Asparagine (N) — a positively-charged primary-amine-bearing residue replaced by a smaller polar amide. Loss of positive charge and reduced side-chain length, but H-bonding capacity preserved.
Position in the protein
C-terminal lumenal domain · position 705 sits in the ER lumen in a well-folded region (pLDDT 90).

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.66 kcal/mol — fold survives. AlphaMissense 0.990 confirms severe functional consequence.

The mechanism is loss of a long-range electrostatic/H-bond contact (K705 to T778 or Q819) that the wild-type residue's extended side chain made. Therapeutic strategy: site-directed small molecules that bridge the K705-T778-Q819 microregion, restoring the long-range contact the wild-type lysine provided.

This is a good example of how the Atlas's PDB neighbor analysis surfaces distal contacts that sequence-based analysis would miss. T778 is 73 residues away from K705 in sequence but only 3.6 Å away in structure.

Why this matters

K705N's mechanism — loss of long-range structural contact via a long-side-chain residue — is one the Atlas captures well through its 5 Å neighbor extraction. The wild-type lysine reaches across the folded domain to contact residues 73 sequence positions away. Drug discovery here targets the cross-domain contact rather than the local position alone.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the K705N PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download K705N PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal